SCHEMBL7209672

SCHEMBL7209672

CCCCCCCCC(CCC)C(N)=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.63
CA1 P00915 1/20 0.63
GRIK1 P39086 2/20 0.52
GRIK2 Q13002 2/20 0.52
SLC1A2 P43004 1/20 0.48
SLC1A1 P43005 1/20 0.48
GPR84 Q9NQS5 7/20 0.47
FFAR1 O14842 1/20 0.47
EPHX1 P07099 1/20 0.46
MAPT P10636 1/20 0.45
LCK P06239 1/20 0.45
PPARD Q03181 1/20 0.45
ZDHHC20 Q5W0Z9 1/20 0.45
ZDHHC2 Q9UIJ5 1/20 0.45
CHRM1 P11229 1/20 0.44
AKR1A1 P14550 1/20 0.44
CHRM3 P20309 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
ADRA1A P35348 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6251202 1.00 CA2 (0.63) CA2CA1GRIK1GRIK2SLC1A2
SCHEMBL3861238 1.00 CA2 (0.63) CA2CA1GRIK1GRIK2SLC1A2
SCHEMBL7204823 1.00 CA2 (0.63) CA2CA1GRIK1GRIK2SLC1A2
SCHEMBL3855790 1.00 CA2 (0.63) CA2CA1GRIK1GRIK2SLC1A2
SCHEMBL7212250 1.00 CA2 (0.63) CA2CA1GRIK1GRIK2SLC1A2
SCHEMBL1672036 1.00 CA2 (0.63) CA2CA1GRIK1GRIK2SLC1A2
SCHEMBL276768 1.00 CA2 (0.63) CA2CA1GRIK1GRIK2SLC1A2
SCHEMBL490747 1.00 CA2 (0.63) CA2CA1GRIK1GRIK2SLC1A2
SCHEMBL3452084 1.00 CA2 (0.63) CA2CA1GRIK1GRIK2SLC1A2
Hydrochloric Acid SCHEMBL25419337 0.98 CA2 (0.61) CA2CA1GRIK1GRIK2SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6605638-B1 Treating multidrug resistant tumors; increasing drug bioavailability D-PHARM LIMITED (IL) 2003-08-12 US claimed
US-11993600-B2 Saturated spirocyclics as antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2024-05-28 US disclosed
WO-2023107419-A1 SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. (US) 2023-06-15 WO disclosed
US-20230174531-A1 SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2023-06-08 US disclosed
EP-4175941-A2 METHODS FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS USING DIGLYCOLAMIDE DERIVATIVES UT-Battelle, LLC (US) 2023-05-10 EP disclosed
US-6605638-B1 Treating multidrug resistant tumors; increasing drug bioavailability D-PHARM LIMITED (IL) 2003-08-12 US disclosed
EP-0912465-A1 IMPROVED LITHIUM AND AMINE DISSOLVING METAL REDUCTION Allergan Sales, Inc. (US) 1999-05-06 EP disclosed
WO-1998003451-A1 IMPROVED LITHIUM AND AMINE DISSOLVING METAL REDUCTION ALLERGAN SALES, INC. (US) 1998-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11993600-B2 Saturated spirocyclics as antiviral agents ACE, ACE2, PKD1 CA2 1149/4885CA1 3044/4885GRIK1 2556/4885
US-20230174531-A1 SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS ACE, ACE2, PKD1 CA2 1149/4885CA1 3044/4885GRIK1 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.